Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Trials

Study Protocol

Robert Tulloh¹  Maria Mossberg²  Robin Kahn²  Filip Kucera³  Cara Purvis⁴  Yolanda Collaco Moraes⁴  Molly Pursell⁴  Ann Sarah Walker⁴  Marta Merida Morillas⁴  Roisin Connon⁴  Mandy Wan⁵  Jethro Herberg⁶  Michael Levin⁶  Veronica Swallow⁷  Rachael McCormack⁸  Paul Brogan⁹  Despina Eleftheriou⁹  Nigel Klein⁹  Joseph F. Standing⁹ 

[1] Bristol Heart Institute, Bristol, UK;Department of Paediatrics, Lund University, Clinical Sciences, Lund, Sweden;Great Ormond Street Hospital, London, UK;Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College London (UCL), London, UK;Pharmacy Department, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK;Institute of Pharmaceutical Science, King’s College London, London, UK;Section of Paediatric Infectious Diseases, Imperial College London, London, UK;Sheffield Hallam University, Sheffield, UK;Societi Foundation CIO, The UK Foundation for Kawasaki Disease, Newark, UK;UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, WC1N 1EH, London, UK;

关键词: Kawasaki disease;    Corticosteroids;    Coronary artery aneurysms;   

DOI  :  10.1186/s13063-022-07051-9

 received in 2022-10-28, accepted in 2022-12-23,  发布年份 2022

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 3